Coherus Set Sights On Taking Fifth Of US Pegfilgrastim Market
Having made a strong start with sales of over $120m in its first six months on the market, Coherus believes its Udenyca biosimilar could end 2019 with more than a fifth of the US pegfilgrastim market by volume.
You may also be interested in...
Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.
Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.
Initial market signals from Sandoz’ US launch of its Ziextenzo pegfilgrastim biosimilar are promising, global Biopharmaceuticals head Pierre Bourdage told Generics Bulletin.